Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Accumulated Expenses: 2014-2024

Historic Accumulated Expenses for KalVista Pharmaceuticals (KALV) over the last 6 years, with Dec 2024 value amounting to $18.9 million.

  • KalVista Pharmaceuticals' Accumulated Expenses was N/A to $18.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $18.9 million, marking a year-over-year change of. This contributed to the annual value of $12.4 million for FY2024, which is N/A change from last year.
  • KalVista Pharmaceuticals' Accumulated Expenses amounted to $18.9 million in Q4 2024, which was up 22.73% from $15.4 million recorded in Q4 2024.
  • Over the past 5 years, KalVista Pharmaceuticals' Accumulated Expenses peaked at $18.9 million during Q4 2024, and registered a low of $4.9 million during Q1 2020.
  • For the 2-year period, KalVista Pharmaceuticals' Accumulated Expenses averaged around $13.1 million, with its median value being $12.4 million (2024).
  • Over the last 5 years, KalVista Pharmaceuticals' Accumulated Expenses had its largest YoY gain of 44.80% in 2020, and its largest YoY loss of 3.40% in 2020.
  • Quarterly analysis of 4 years shows KalVista Pharmaceuticals' Accumulated Expenses stood at $6.9 million in 2020, then climbed by 8.39% to $5.3 million in 2021, then reached $11.7 million in 2023, then soared by 31.79% to $18.9 million in 2024.
  • Its last three reported values are $18.9 million in Q4 2024, $15.4 million for Q4 2024, and $10.4 million during Q3 2024.